These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38654469)

  • 41. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
    Wilkins D; Langedijk AC; Lebbink RJ; Morehouse C; Abram ME; Ahani B; Aksyuk AA; Baraldi E; Brady T; Chen AT; Chi H; Choi EH; Cohen R; Danilenko DM; Gopalakrishnan V; Greenough A; Heikkinen T; Hosoya M; Keller C; Kelly EJ; Kragten-Tabatabaie L; Martinón-Torres F; de Los Santos AHM; Nunes MC; Palomino MA; Papenburg J; Pernica JM; Richmond P; Stein RT; Tuffy KM; Verwey C; Esser MT; Tabor DE; Bont LJ;
    Lancet Infect Dis; 2023 Jul; 23(7):856-866. PubMed ID: 36940703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States.
    Yu T; Padula WV; Yieh L; Gong CL
    Pediatr Neonatol; 2024 Mar; 65(2):152-158. PubMed ID: 37758594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.
    Domachowske JB; Khan AA; Esser MT; Jensen K; Takas T; Villafana T; Dubovsky F; Griffin MP
    Pediatr Infect Dis J; 2018 Sep; 37(9):886-892. PubMed ID: 29373476
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Respiratory Syncytial Virus Prevention: A New Era of Vaccines.
    Lee CYF; Khan SJ; Vishal F; Alam S; Murtaza SF
    Cureus; 2023 Sep; 15(9):e45012. PubMed ID: 37829940
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medically Attended Illness due to Respiratory Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020.
    Gantenberg JR; van Aalst R; Zimmerman N; Limone B; Chaves SS; La Via WV; Nelson CB; Rizzo C; Savitz DA; Zullo AR
    J Infect Dis; 2022 Aug; 226(Suppl 2):S164-S174. PubMed ID: 35968869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Otsuki T; Akada S; Anami A; Kosaka K; Munjal I; Baber J; Shoji Y; Aizawa M; Swanson KA; Gurtman A
    Vaccine; 2024 Jun; ():. PubMed ID: 38853036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?].
    Novoa Pizarro JM; Lindemann Tappert BC; Luchsinger Farías VR; Vargas Munita SL
    Andes Pediatr; 2023 Dec; 94(6):672-680. PubMed ID: 38329302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.
    Carbonell-Estrany X; Bont L; Doering G; Gouyon JB; Lanari M
    Eur J Clin Microbiol Infect Dis; 2008 Oct; 27(10):891-9. PubMed ID: 18629558
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
    Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
    Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
    Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Hemming VG
    Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
    Garegnani L; Styrmisdóttir L; Roson Rodriguez P; Escobar Liquitay CM; Esteban I; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013757. PubMed ID: 34783356
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).
    Straňák Z; Saliba E; Kosma P; Posfay-Barbe K; Yunis K; Farstad T; Unnebrink K; van Wyk J; Wegzyn C; Notario G; Kalus S; Campbell FJ
    PLoS One; 2016; 11(6):e0157446. PubMed ID: 27310438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.